The proceeds will be used to launch a new diagnostic instrument, a breast cancer monitoring assay, and proprietary multiplex immunofluorescence reagent kits.

The firm said that it slashed its GAAP EPS guidance and made a smaller cut to its non-GAAP EPS guidance in response to US tariffs and other geopolitical conditions.

The firm raised a total of $13.5 million in its Series A equity financing round, which will go toward growing and advancing its neurodegenerative disease testing business.

NEW YORK – Eight German associations are calling for changes to be made to the European In Vitro Diagnostics Regulation (IVDR ...

NEW YORK – Uppsala University spinout Readily Diagnostics is using technology built off 30 years of research as the basis of a point-of-care, instrument-free test that would detect and differentiate ...

Of the 30 companies on the list, 17 saw their stock prices decrease, 11 saw their share prices increase, and two had their stock prices remain flat.

The former True Health Diagnostics executives were accused of participating in a scheme that paid Texas physicians for blood test referrals.

Last week, readers were most interested in a story about Akoya's collaboration to identify markers predictive of response to checkpoint inhibitor therapy.

NEW YORK – With its combination immunoassay and qPCR blood test, Mursla Bio intends to identify liver cancers earlier by detecting microRNA targets within extracellular vesicles. Last week, Mursla ...

In one case, a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other, a firm paid and received kickbacks for unnecessary genetic testing.

With the certification from the NYS Clinical Laboratory Evaluation Program, the company said the test is now available throughout the US.